S.M.A.R.T.® Vascular Stent Systems Receive FDA Approval for Use in SFA
S.M.A.R.T.®Vascular Stent Systems Receive FDA Approval for Use in SFA
First stent in the U.S. with both SFA and Iliac indications
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Cordis Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved the S.M.A.R.T.® CONTROL® Vascular Stent Systems for use in the superficial femoral artery (SFA) and/or the proximal popliteal artery (PPA). The S.M.A.R.T.® Stent, which has been approved for peripheral indication in international markets since 1999, is now the first stent in the Unites States with both Iliac and SFA indications.
The clinical data supporting the FDA approval of the S.M.A.R.T.® Stent for use in the peripheral vasculature was obtained through the STROLL Investigational Device Exemption (IDE) trial that enrolled 250 patients at 39 clinical sites within the U.S. In the study, freedom from clinically driven target lesion revascularization (TLR) at one year was 87.4%. The 12-month primary patency rate for the S.M.A.R.T.® Stent was 81.7% by Kaplan Meier estimate. The study results show no major adverse events at 30 days and a low one-year stent fracture rate of 2.0 percent. In addition, all stent fractures were Type I, least severe, and there were no incidents of more severe stent fractures (Type II-V).
"The STROLL trial demonstrates one year patency rates of ~81% and a very low fracture rate," said Dr. William A. Gray, Director of Endovascular Services, Cardiovascular Research Foundation, New York, and co-national principal investigator of the STROLL study. "These outcomes both meet and exceed our expectations for patients with symptomatic disease of the superficial femoral artery."
In addition to the excellent clinical outcomes in the STROLL study, Health Related Quality of Life (QOL) Surveys also showed an improvement in patient outcomes. This included minimal or no signs of PAD* in 3 of 4 patients (as measured using Rutherford-Becker classification), and normal Ankle Brachial Index (ABI) in 4 of 5 patients at 1 year.1
"We are very pleased to offer an expanded indication for the S.M.A.R.T.® Stent," said Shlomi Nachman, Worldwide President, Cordis Corporation. "Our goal is to continue to make expanded indications and new products available to our customers so they may bring these innovations to their patients."
One of the most common vascular diseases, Peripheral Arterial Disease (P.A.D.), occurs when leg arteries become narrowed or blocked by plaque. These blockages can result in severe pain, limited physical mobility and non-healing leg ulcers. According to the American Heart Association, approximately 10 million people in the U.S. suffer from P.A.D.
The STROLL study and the SFA indication for the SMART Stent represent the latest commitments by Cordis to continue its groundbreaking work in the fight against vascular disease.
Dr. Gray is compensated for his services as a member of the company's scientific advisory board and provides other consulting services.
About Cordis Corporation
Cordis Corporation, part of the Johnson & Johnson family of companies, is a worldwide leader in the development and manufacture of interventional vascular technology. Through the company's innovation, research and development, Cordis partners with interventional cardiologists worldwide to treat millions of patients who suffer from vascular disease. More information about Cordis Corporation can be found at www.cordis.com.
*Defined as Rutherford-Becker classification 0 or 1.
Reference: 1. Data on file, Cordis Corporation.
For Cordis Corporation
KEYWORDS: United States North America New Jersey
The article S.M.A.R.T.® Vascular Stent Systems Receive FDA Approval for Use in SFA originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.